What a difference a few months can make. When KPMG, the auditors of Nuritas, signed of on the company’s 2020 accounts earlier this year, the accountancy firm stated “that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern”. Now, the Irish biotechnology company has closed a massive $45 million funding round to help accelerate its global expansion. The investment is led by Chicago-based Cleveland Avenue, and includes backing from Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund (ECBF), Vertex Holdings, Nutresa Ventures / Veronorte and CJ. Founded by Don Thompson,…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .